Aberrant activation of the MET/HGF pathway is involved in the development and metastatic progression of various tumors, and this pathway constitutes the mechanism by which cancer patients acquire resistance to targeted treatment and attenuates tumor response to immunotherapy (6–11). This evidence concerns the gene MET and cancer.